- 18 Apr 2018 Kymab presents data on two of its immuno-oncology antibodies, providing further evidence of the strength of its franchise
- 12 Jan 2018 Kymab ‘top European biotech to watch’ in 2018
- 4 Dec 2017 Anti-PD-L1 antibody KY1003 shows anti-tumour efficacy
- 8 Nov 2017 KY1044 strongly inhibits tumour growth in models
- 21 Sep 2017 KY1005 impressive in acute GVHD model
- 31 Jul 2017 Kymab's KY1005 antibody in clinical trial
- 23 Jan 2017 Arndt Schottelius appointed Executive VP R&D
- 9 Jan 2017 Kymab expands Infectious Disease Programmes
- 5 Dec 2016 Antibody shows dramatic post-transplant benefit
- 8 Sep 2016 Kymab's early steps towards HIV vaccine
We use cookies on our website. Carry on browsing if you’re happy with this or find out more
Featured article: Kymab Announces Presentations at the 24th EHA Annual Congress
Two Company-sponsored oral and poster abstracts to be presented on KY1049 and IntelliSelect® Bispecifics platform
Read article
Featured article: Kymab Poster on Adaptive Phase 1/2 Clinical Trial for KY1044 anti-ICOS Program at 2019 ASCO Meeting
Clinical trial initiated in February 2019 in the U.S., MD Anderson Cancer Center and Sarah Cannon Research Institute Phase ...
Read article